Paulina Pidikova, Pavel Svitok and Iveta Herichova
Objective. Epidemiological studies confirm that hypertensive patients respond differently to renin-angiotensin system (RAS) inhibition depending on their gender. The aim of present work is to focus on sex-dependent differences in RAS regulation under conditions of increased salt intake.
Method. To investigate RAS, we measured the expression of angiotensinogen (Agt) mRNA, angiotensin receptor type 1 (AT1) mRNA and mitochondria assembly receptor (MasR) in the liver of rats under control conditions and after feeding with a salt diet (2% NaCl). In parallel, vascular endothelial growth factor A (VEGF-A) mRNA was analyzed.
Results. Regression analysis revealed sex-dependent differences in the correlation between mRNA expression of AT1 and that of Agt, MasR and VEGF-A in both groups. There was a significant negative correlation between AT1 and Agt mRNA expression in the male control group, but this correlation disappeared in males exposed to a salt diet. In females, AT1 and Agt expression correlated only in the group exposed to the salt diet. In control males, there was a borderline trend to correlation between AT1 and MasR mRNA expression. The correlation between AT1 and VEGF-A mRNA expression was significant only in the control females, however, after exposure to a salt diet, this correlation diminished.
Conclusions. We hypothesize that RAS components expression is compensated differently in males and females. The observed loss of compensatory relationships in RAS between AT1 and Agt and AT1 and MasR in male rats under a salt diet can contribute to the differences observed in human with hypertension associated with an unhealthy diet.
Xing Liu, Yang Ming, Ligang Chen, Lilei Peng, Qiang Ye, Shuzhan Zheng and Zhongcai Fan
Background: Accumulating evidence suggests that CD62L and CD 106 are positively expressed on the surface of mesenchymal stem cells (MSCs). It has been reported that both receptors can be induced by minor necrosis factor- ⃞ (TNF-α). granulocyte-colony stimulating factor (G-CSF). and vascular endothelial growth factor (VEGF) on leucocytes. However, whether these stimulations induce CD62L and CD 106 expressions on MSCs is still unknown. Thus, in the present study we investigated the effects of TNF-α. G-CSF and VEGF on CD62L and CD 160 expressions on the surface of MSCs.
Method: MSCs were isolated from rat bone marrows, and treated with different concentrations of TNF-α (0.1.1 and 10 ng/mL), G-CSF and VEGF (1.10. and 100 ng/mL) for 12 and 24 hours respectively. Then the expressions of CD62L and C'D 106 on the surface of MSCs were analyzed by flow cytometry.
Results: Immunochemistry assay showed positive CD90 but negative CD45 in the MSCs. Flow cytometry analysis suggested that TNF-α and G-CSF could induce CD62L and CD106 expressions on the surface of MSCs in a dose-dependent manner, but not in a time-dependent manner. Further, all the concentrations of VEGF had no significant effect on the CD62L and CD106 expressions.
Conclusion: CD62L and CD106 can be induced by TNF-α and G-CSF on the surface of MSCs. but not by VEGF. These findings can help improve BM-MSC migration capability and therapeutic efficiencies of MSC transplantation.
Alicja Gluszko, Shafaq M. Mirza, Katarzyna Piszczatowska, Ireneusz Kantor, Marta Struga and Miroslaw J. Szczepanski
factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer . 2001;85(1):93-7.
52. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol . 2001;80(2):181-8.
53. Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, Matikainen MT, et al. Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular
., Cohen A., Zagouri F., Dimopoulos M. A., Bamias A.
Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece
Introduction : Axitinib is a selective inhibitor of VEGF1,-2 and -3 receprors, which is approved as a second line therapy for patients with metastatic Renal cell carcinoma (mRCC).
Aim : Study of the efficacy and safety of Axitinib as 3 rd line therapy and beyond
Methods : This is a retrospective study of patients with mRCC who received Axitinib to our department as 3rd line or beyond from December of 2013- January of 2017. Patients